MT2021-33: Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial, with Cross-Over, of Posoleucel (ALVR105) for the Treatment of Adenovirus Infection in Pediatric and Adult Participants Receiving Standard of Care Following Allogeneic Hematopoietic Cell Transplantation


To compare the percent of participants who have clearance of AdV viremia at Day 29 in participants receiving posoleucel and standard of care to that in participants receiving placebo and standard of care.

I'm interested

This study is NOT accepting healthy volunteers

Adenovirus Infection

ALVR105, Adenoviremia, Adenovirus, Allogeneic Hematopoietic Cell Transplant, Clinics and Surgery Center (CSC), Posoleucel, Stem cell transplant

Tamara Griffin -
Paul Orchard
Phase III
See this study on